No Detail Found!

Treatment free remission in chronic myeloid leukemia; a practical option

Author(s)
Kaleem Ahmed Dept of Biotechnology, International Islamic University Islamabad, Pakistan
Raheel Iftikhar Clinical Hematologist and Bone Marrow Physician, Armed Forces Bone Marrow Transplant Center,Rawalpindi, Pakistan
Zafar Iqbal Department of Molecular Genetics & Hematology/Oncology, College of Applied Medical Sciences, King Saud Bin Abdulaziz Univ. for Health Sciences,
Muhammad Arshad Dept.of Biological Sciences, International Islamic University Islamabad, Pakistan
Aleem Ahmed Dept.of Biotechnology, International Islamic University Islamabad, Pakistan
Abstract
Chronic myeloid leukemia (CML) is a type of blood malignancy. Unlike some other diseases and cancers, the treatment for CML typically spans many years. Patients achieving and sustaining a deep molecular response may be candidates for treatment stoppage. This concept also known as treatment free remission (TFR) is a new concept in CML management and of late has become a major goal. TFR has also taken the center stage owing to its implications in reducing health and financial burden being imposed by the disease. Numerous clinical trials have made an attempt to study as to which patients are the best candidates for treatment free remission and what percentage of such patients either stay in remission stage or face relapse. Findings of the trials suggest around 45-60% of patients being able to achieve TFR whereas the relapse mostly occurred in first six months of treatment stoppage. Nevertheless, almost all patients who were reinitiated on Tyrosine kinase inhibitors (TKIs) showed molecular response. Certain clinical and molecular biomarkers are thought to be linked to increase probability of TFR. In this review we attempt to discuss both clinical and molecular markers associated with TFR in CML.
Publication Details
Page(s) 34-42
DOI DOI not available
Published Journal: Journal of Haematology and Stem Cell Research, Volume: 3, Issue: 1, Year: 2023

Request the full text from PASTIC

Keywords
Chronic myeloid leukemia, Relapse, Tyrosine kinase inhibitors., Treatment free remission
0

Citations

0

Downloads

59

Views